Paper · 42286159
Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.
Hofmann E and 18 others. NPJ Precis Oncol, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study. Papers, record 42286159. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42286159
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35,658,604 | Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. | Thyroid | 2022 | https://conductscience.org/library/papers/35658604 | PubMed |
| 2 | 34,611,482 | Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. | Oncotarget | 2021 | https://conductscience.org/library/papers/34611482 | PubMed |
| 3 | 37,884,744 | NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology. | NPJ Precis Oncol | 2023 | https://conductscience.org/library/papers/37884744 | PubMed |
| 4 | 25,627,962 | Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. | J Transl Med | 2015 | https://conductscience.org/library/papers/25627962 | PubMed |
| 5 | 27,226,682 | Quality of life of patients surgically treated for ameloblastoma. | Niger Med J | 2016 | https://conductscience.org/library/papers/27226682 | PubMed |
| 6 | 35,050,789 | Tumor Regression After Treatment With Lenvatinib in FGFR2-Mutated Ameloblastoma. | JCO Precis Oncol | 2020 | https://conductscience.org/library/papers/35050789 | PubMed |
| 7 | 28,919,011 | Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28919011 | PubMed |
| 8 | 21,183,792 | Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. | J Clin Invest | 2011 | https://conductscience.org/library/papers/21183792 | PubMed |
| 9 | 20,970,910 | Metastasizing (malignant) ameloblastoma: review of a unique histopathologic entity and report of Mayo Clinic experience. | J Oral Maxillofac Surg | 2010 | https://conductscience.org/library/papers/20970910 | PubMed |
| 10 | 26,796,877 | Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy. | Eur Arch Otorhinolaryngol | 2016 | https://conductscience.org/library/papers/26796877 | PubMed |
1 to 10 of 52
See all 52 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| FGFR2 | 2,263 | PubTator's text mining | https://conductscience.org/library/genes/2263 | NCBI Gene |
| HRAS | 3,265 | PubTator's text mining | https://conductscience.org/library/genes/3265 | NCBI Gene |
| PIK3CA | 5,290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
| SMO | 6,608 | PubTator's text mining | https://conductscience.org/library/genes/6608 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42286159
GET https://conductscience.org/api/papers/v1/42286159/references?page=2